Curia, formerly AMRI, a contract research, development and manufacturing organization, announced that Integrity Bio and LakePharma, two companies acquired last year, have fully transitioned to the Curia brand. This reflects the organizational integration of the acquired companies into Curia and its provision of comprehensive biologics discovery, development and manufacturing services. Curia acquired Integrity Bio in August 2021 and LakePharma in September 2021. 
 
“The addition of LakePharma and Integrity Bio demonstrate our commitment to expanding and deepening our biologics capabilities,” said Curia Chairman and CEO John Ratliff. “We have moved quickly to integrate our expanded organization so we can provide comprehensive technology and scientific solutions that enable customers to advance their biologics candidates from R&D through manufacturing. More than a name change, the combined Curia organization brings a singular focus on creating a distinctive customer experience designed to accelerate projects and navigate complexity, all driven by a shared commitment to the mission of improving patients’ lives.” 
 
The respective companies’ capabilities can be found on Curia’s site: www.curiaglobal.com. Integrity Bio and Lake Pharma’s legal entity names will begin transitioning immediately.
 
Curia, formerly AMRI, provides products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia has 3,700 employees at 29 locations across the U.S., Europe and Asia.